DOCSLIB.ORG

Surgical Decolonization and Prophylaxis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Surgical Decolonization and Prophylaxis Surgical Decolonization and Prophylaxis SurgicalSurgical Decolonization Decolonization and Prophylaxis and Prophylaxis DECOLONIZATION DECOLONIZATION Nasal Screening Result Recommended Intervention Nasal Screening Result Recommended Intervention MRSA Negative • No decolonization required MSSAMRSA NegativeNegative • No decolonization required MSSA PositiveNegative • Intranasal mupirocin twice daily x 5 days MSSA Positive • Intranasal mupirocin twice daily x 5 days MRSA Positive • Intranasal mupirocin twice daily x 5 days, MRSA Positive AND• Intranasal mupirocin twice daily x 5 days, •ANDChlorhexidine bathing one day prior to surgery ANTIMICROBIAL• ChlorhexidinePROPHYLAXISbathing one day prior to surgery ANTIMICROBIAL PROPHYLAXIS CLINICAL CONSIDERATIONS • Preoperative dose-timing CLINICAL CONSIDERATIONS • PreoperativeWithin 60 minutesdose-timing of surgical incision WithinExceptions: 60 minutes vancomycin of surgicaland fluoroquinolones incision within 120 minutes of surgical incisionExceptions: vancomycin and fluoroquinolones within 120 minutes of surgical • Weightincision-based dosing • WeightCefazolin-based: 2 gm dosingfor patients <120 kg, and 3 gm for patients ≥120 kg Vancomycin:Cefazolin: 2 gm usefor ABW patients <120 kg, and 3 gm for patients ≥120 kg Gentamicin:Vancomycin: use use ABW ABW unless ABW is >120% of their IBW, in which case use AdjBWGentamicin:(see below use ABW for equation)unless ABW is >120% of their IBW, in which case use • DurationAdjBW of(see prophylaxis below for equation) • DurationA single of dose, prophylaxis or continuation for <24 hours is recommended A single dose, or continuationI NTRAfor <24-OPERATIVE hours isREDOSING recommended • Required if the duration of procedureINTRA-OPERATIVE exceeds twoREDOSING half-lives of the drug or if there • isRequired extensive if theblood duration loss during of procedure the procedure exceeds (>1500 two half mL)-livesŦ of the drug or if there • Recommendation:is extensive blood lossuse duringthe same the antibiotic procedure dose (>1500 and mL)measureŦ the redosing interval • fromRecommendation: the time of administration use the same of antibiotic the preoperative dose and dose, measure not the redosingtime of incision interval ABW=from actual the body timeweight; of AdjBW administration= adjusted body weight; of the IBW preoperative= ideal body weight; dose, MRSA= Methicillinnot the- resistanttime of Staphylococcus incision aureus; MSSA= Methicillin-susceptible Staphylococcus aureus ABW= actual body weight; AdjBW= adjusted body weight; IBW= ideal body weight; MRSA= Methicillin-resistant Staphylococcus Ŧaureus Redosing; MSSA may= Methicillinnot be necessary-susceptible for patients Staphylococcus with poor aureus renal function (CrCl <30mL/min) Ŧ Redosing may not be necessary for patients with poor renal function (CrCl <30mL/min) IBW Calculation: AdjBW Calculation: Male = 50 kg + [2.3 kg for each inch over 5 feet] AdjBW = 0.4 (ABW-IBW) + IBW IBW Calculation: AdjBW Calculation: Female = 45 kg + [2.3 kg for each inch over 5 feet] Male = 50 kg + [2.3 kg for each inch over 5 feet] AdjBW = 0.4 (ABW-IBW) + IBW Female = 45 kg + [2.3 kg for each inch over 5 feet] References: 1. Schweuzer ML, Chiang H, Septimus E, Moody J, Braun B, Hafner J, et al. Association of a Bundled Intervention with Surgical Site Infections References:Among Patients Undergoing Cardiac, Hip, or Knee Surgery (STOP SSI – Study to Optimally Prevent SSI in Select Cardiac and Orthopedic 1. Procedures).Schweuzer ML, JAMA Chiang2015; H, 313(21):Septimus 2162E, Moody-2171. J, Braun B, Hafner J, et al. Association of a Bundled Intervention with Surgical Site Infections 2. ChenAmong AF, Patients Wessel UndergoingCB, Rao N. Staphylococcus Cardiac, Hip, or aureus Knee SurgeryScreening (STOP and SSI Decolonization – Study to Optimally in Orthopaedic PreventSurgery SSI in Select and Reduction Cardiac and of OrthopeSurgical dicSite Infections.Procedures). Clin JAMAOrthop2015;Relat 313(21):Res 2013; 2162 471:-2171. 2383-2399. 3.2. BratzlerChen AF,DW, Wessel Dellinger CB, Rao EP,N. Olsen Staphylococcus KM, Perl TM, aureus AuwaerterScreeningPG, Bolonand DecolonizationMK, et al. Clinical in Orthopaedic practice guidelinesSurgery forand antimicrobial Reduction of prophylaxis Surgical Site in surgery.Infections. Am Clin J HealthOrthop SystRelatPharmRes 2013; 70:195471: 2383-283.-2399. 3. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195-283. PAGE 26 Antimicrobial Surgical Prophylaxis AntimicrobialAntimicrobial Surgical REDOSINGSurgical ProphylaxisRECOMMENDATIONS Prophylaxis Antibiotic REDOSINGHalf-life R(hours)ECOMMENDATIONS Redosing Interval (hours) Ampicillin/sulbactamAntibiotic 0.8-1.3 Half-life (hours) 2 Redosing Interval (hours) CefazolinAmpicillin/sulbactam 1.20.8-2.21.3 42 CefoxitinCefazolin 0.71.2-1.12.2 24 CiprofloxacinCefoxitin 30.7-7-1.1 Not2 necessary ClindamycinCiprofloxacin 23-47 6Not necessary GentamicinClindamycin 2-34 Not6 necessary MetronidazoleGentamicin 62-83 Not necessary VancomycinMetronidazole 46-8 Not necessary SURGICAL ALTERNATIVES FOR PATIENTS WITH BETA-LACTAM Vancomycin RECOMMENDED4-8 AGENTS Not necessary PROCEDURE ALLERGY SURGICAL ALTERNATIVES FOR PATIENTS WITH BETA-LACTAM Laparoscopic, NoneRECOMMENDED AGENTS None PROCEDURE ALLERGY low-risk Laparoscopic, CefazolinNone , cefoxitin, ClindamycinNone or vancomycin + aminoglycoside highlow--riskrisk cefotetan, ceftriaxone, or aztreonam or fluoroquinolone Laparoscopic, ampicillin/Cefazolin, cefoxitinsulbactam, Clindamycin or vancomycin + aminoglycoside high-risk cefotetan, ceftriaxone, or aztreonam or fluoroquinolone Small intestine, ampicillin/Cefazolin sulbactam Clindamycin + aminoglycoside or nonobstructed aztreonam or fluroquinolone Small intestine, Cefazolin Clindamycin + aminoglycoside or Smallnonobstructed intestine, Cefazolin + metronidazole, Metronidazoleaztreonam or fluroquinolone+ aminoglycoside or obstructed cefoxitin, cefotetan fluoroquinolone Small intestine, Cefazolin + metronidazole, Metronidazole + aminoglycoside or Herniaobstructed repair Cefazolincefoxitin, cefotetan Clindamycinfluoroquinolone, vancomycin ColorectalHernia repair Cefazolin + metronidazole, Clindamycin,+ vancomycin aminoglycoside or cefoxitin, cefotetan, aztreonam or fluroquinolone; Colorectal ampicillin/sulbactamCefazolin + metronidazole, , MetronidazoleClindamycin + aminoglycoside+ aminoglycoside or or ceftriaxonecefoxitin, cefotetan+ , fluoroquinoloneaztreonam or fluroquinolone; metronidazoleampicillin/sulbactam, ertapenem, Metronidazole + aminoglycoside or ceftriaxone + fluoroquinolone Head and neck, Nonemetronidazole, ertapenem None Jen - thisclean page is too Head and neck, None None long. You’llHeadclean haveand neck, to Cefazolin, cefuroxime Clindamycin shorten placementit somehow. of prostheticHead and neck, Cefazolin, cefuroxime Clindamycin placement of Cleanprosthetic- Cefazolin + metronidazole, Clindamycin contaminated cefuroxime + cancerClean- surgery metronidazoleCefazolin + metronidazole, , Clindamycin contaminated ampicillin/sulbactamcefuroxime + cancer surgery metronidazole, ampicillin/sulbactam References: 1. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195-283. References: 1. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195-283. PAGE 27 Antimicrobial Surgical Prophylaxis AntimicrobialAntimicrobial Surgical Surgical Prophylaxis Prophylaxis ALTERNATIVES FOR PATIENTS WITH SURGICAL PROCEDURE RECOMMENDED AGENTS BETA-LACTAM ALLERGY ALTERNATIVES FOR PATIENTS WITH SURGICAL PROCEDURE RECOMMENDED AGENTS Ortho: clean hand, None None BETA-LACTAM ALLERGY knee, or foot not Ortho: clean hand, None None involving implantation knee, or foot not of foreign materials involving implantation ofOrtho: foreign implantation materials of Cefazolin Clindamycin, vancomycin foreign material and/or Ortho: implantation of Cefazolin Clindamycin, vancomycin total joints foreign material and/or totalUrologic jointswith risk Fluoroquinolone, Aminoglycoside +/- clindamycin factors for infection TMP/SMX, cefazolin Urologic with risk Fluoroquinolone, Aminoglycoside +/- clindamycin factorsUrologic, for clean infection without TMP/SMXCefazolin*, cefazolin Clindamycin, vancomycin entry into urinary tract Urologic, clean without Cefazolin* Clindamycin, vancomycin entryUrologic into involving urinary tract Cefazolin ± Clindamycin ± aminoglycoside or implanted prosthesis aminoglycoside, aztreonam, vancomycin ± Urologic involving Cefazolin ± Clindamycin ± aminoglycoside or cefazolin ± aztreonam, aminoglycoside or aztreonam implanted prosthesis aminoglycoside, aztreonam, vancomycin ± ampicillin/sulbactam cefazolin ± aztreonam, aminoglycoside or aztreonam Urologic, clean with ampicillin/sulbactamCefazolin* Fluoroquinolone, aminoglycoside ± entry into urinary tract clindamycin Urologic, clean with Cefazolin* Fluoroquinolone, aminoglycoside ± entryUrologic, into clean urinary- tract Cefazolin + clindamycinFluoroquinolone, aminoglycoside + contaminated metronidazole, cefoxitin metronidazole or clindamycin Urologic, clean- Cefazolin + Fluoroquinolone, aminoglycoside + TMP/SMX=contaminated trimethoprim/sulfamethoxazolemetronidazole, cefoxitin metronidazole or clindamycin TMP/SMX=*Addition of trimethoprim/ a single dose sulfamethoxazoleof an aminoglycoside may be recommended for placement of prosthetic material (e.g. penile prosthesis) *Addition of a single dose of an aminoglycoside may be recommended for placement of prosthetic material (e.g. penile prosthesis) References: 1. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195-283. References: 1. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195-283. PAGE 28.
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Antibiotic Review
    8/28/19 Disclosure 2 E. Monee’ Carter-Griffin DNP, MA, RN, ACNP-BC Antibiotic has no financial relationships with commercial Review interests to disclose. Any unlaBeled and/or E. Monee’ Carter-Griffin, DNP, MA, RN, ACNP-BC unapproved uses of drugs or products will Be Associate Chair for Advanced Practice Nursing disclosed. University of Texas at Arlington, College of Nursing & Health Innovation Dallas Pulmonary & Critical Care, PA • Identify the general characteristics of • SusceptiBility à determine which antibiotics. antibiotics a bacteria is sensitive to • Discuss the mechanism of action, • à pharmacokinetics, and spectrum of activity MIC lowest concentration of drug that inhiBits growth of the Bacteria for the most common antiBiotic drug classes. Antibiotic Objectives • Identify commonly prescriBed antiBiotics • Trough à lowest concentration of within the drug classes including dosage Lingo drug in bloodstream range and indication for prescribing. – Collect prior to administration of • Identify special considerations for specific drug antibiotics and/or drug classes. • Peak à highest concentration of • Practice appropriate prescriBing for common drug in bloodstream bacterial infections. • Review Basic antiBiotic stewardship 3 4 principles. • Penicillins • Bactericidal or bacteriostatic • Cephalosporins • Narrow or Broad spectrum • Carbapenems General • Can elicit allergic responses Antibiotic • MonoBactam Characteristics • Affect normal Body flora Drug Classes • Macrolides • Fluoroquinolones • Sulfonamides • Tetracyclines 5 6 1 8/28/19 • Penicillins – Natural penicillins 8 – Aminopenicillins Penicillins Penicillins – Anti-staphylococcal penicillins • Mechanism of action àbactericidal à – Anti-pseudomonal penicillins interrupts cell wall synthesis 7 • Pharmacokinetics • Spectrum of Activity – Gram positive organisms Natural – Penicillin G à mostly given IM, But Natural • Streptococcus species (e.g. S. Penicillins one variation can Be given IV Penicillins pyogenes) • Poorly aBsorBed via PO • Some enterococcus species (e.g.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Surgical Prophylaxis Antibiotic Recommendations Updated 2017
    Surgical Prophylaxis Antibiotic Recommendations Updated 2017 1. Prophylactic antibiotic is to be initiated within 1 hour prior to incision Exception: Due to the longer infusion time required, initiate vancomycin and ciprofloxacin within 2 hours prior to incision 2. Anesthesia to give preoperative antibiotic dose and document time on anesthesia record. Exception: Antibiotics in Endoscopy, Labor and Delivery and Birth Care Center 3. Chose alternative antibiotic if patient is allergic to recommended first line antibiotic. Avoid giving cefazolin or cefotetan if the patient has allergies to cephalosporins or a life- threatening allergy to penicillin (angioedema, bronchoconstriction, cardiac arrhythmias, hypotension, or respiratory distress) 4. Pediatric Patients: Maximum dose is dose listed for wt <80 kg. For pediatric patients >80 kg, follow adult dosing. 5. For patients colonized with MRSA: Give vancomycin as the pre-op antibiotics for cardiac, vascular, orthopedic, neurological, and head and neck surgeries. For all other surgeries, give vancomycin in addition to the antibiotics listed below. To determine if a patient is colonized with MRSA, please see flow sheet below. 6. Per Clinical Practice Restricted/High Risk Medications with Special Requirements Policy: Pre-operative antibiotics for prophylaxis in adult patients will be automatically substituted to the antibiotics listed on Adult Surgical Pre-Operative Antibiotic Prophylaxis order set #347. For surgeries/procedures not addressed on the order set, anesthesia is to discuss antibiotic selection with the surgeon. 7. Antibiotics listed below are listed in order of preference. The first line antibiotic has been designated with an asterisks(*). Dose Surgical Procedure Drug Pediatrics (<80 kg), Wt <80 kg Wt 80-119 kg Wt ≥ 120 kg If applicable Coronary Artery Bypass Graft Cardiac Surgery cefazolin IV* 1 gm 2 gm 3 gm Vascular Surgery All CABG, Valves and other CV procedures Pacemakers, AICD’s, pocket vancomycin IV (MRSA or 1 gm 1.5 gm 2 gm relocation and lead revisions, allergy) generator replacements.
    [Show full text]
  • Cephalosporins Can Be Prescribed Safely for Penicillin-Allergic Patients ▲
    JFP_0206_AE_Pichichero.Final 1/23/06 1:26 PM Page 106 APPLIED EVIDENCE New research findings that are changing clinical practice Michael E. Pichichero, MD University of Rochester Cephalosporins can be Medical Center, Rochester, NY prescribed safely for penicillin-allergic patients Practice recommendations an allergic reaction to cephalosporins, ■ The widely quoted cross-allergy risk compared with the incidence of a primary of 10% between penicillin and (and unrelated) cephalosporin allergy. cephalosporins is a myth (A). Most people produce IgG and IgM antibodies in response to exposure to ■ Cephalothin, cephalexin, cefadroxil, penicillin1 that may cross-react with and cefazolin confer an increased risk cephalosporin antigens.2 The presence of of allergic reaction among patients these antibodies does not predict allergic, with penicillin allergy (B). IgE cross-sensitivity to a cephalosporin. ■ Cefprozil, cefuroxime, cefpodoxime, Even penicillin skin testing is generally not ceftazidime, and ceftriaxone do not predictive of cephalosporin allergy.3 increase risk of an allergic reaction (B). Reliably predicting cross-reactivity ndoubtedly you have patients who A comprehensive review of the evidence say they are allergic to penicillin shows that the attributable risk of a cross- U but have difficulty recalling details reactive allergic reaction varies and is of the reactions they experienced. To be strongest when the chemical side chain of safe, we often label these patients as peni- the specific cephalosporin is similar to that cillin-allergic without further questioning of penicillin or amoxicillin. and withhold not only penicillins but Administration of cephalothin, cepha- cephalosporins due to concerns about lexin, cefadroxil, and cefazolin in penicillin- potential cross-reactivity and resultant IgE- allergic patients is associated with a mediated, type I reactions.
    [Show full text]
  • A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
    A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through
    [Show full text]
  • INVANZ, INN-Ertapenem
    EMA/665637/2016 EMEA/H/C/000389 EPAR summary for the public Invanz ertapenem This is a summary of the European public assessment report (EPAR) for Invanz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Invanz. For practical information about using Invanz, patients should read the package leaflet or contact their doctor or pharmacist. What is Invanz and what is it used for? Invanz is an antibiotic. It is used in adults and children aged over 3 months to treat the following infections: • infections within the abdomen; • community-acquired pneumonia (infection of the lungs caught away from hospital); • gynaecological infections; • foot infections in diabetes patients. Invanz is also used in adults to prevent infection after colorectal surgery (surgery in the lower part of the bowel, including the rectum). Invanz is used when the bacteria that cause the infection are likely to be killed by the antibiotic. Before using Invanz, doctors should consider official guidance on the appropriate use of antibiotics. Invanz contains the active substance ertapenem. How is Invanz used? Invanz is available as a vial containing a powder which is dissolved before use to make up a solution for infusion (drip) into a vein. It is infused over 30 minutes. The medicine can only be obtained with a prescription. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016.
    [Show full text]
  • Medication Shortages: March 2019
    Medication shortages March 26,2019 Analgesia/Addiction • Fentanyl Citrate (Sublimaze) Injection (Currently in Shortage) • Hydromorphone Hydrochloride Injection, USP (Currently in Shortage) • Ketoprofen Capsules (Currently in Shortage) • Ketorolac Tromethamine Injection (Currently in Shortage) • Methadone Hydrochloride Injection (Currently in Shortage) • Methocarbamol Tablets (Currently in Shortage) • Morphine Sulfate Injection, USP (Currently in Shortage) • Promethazine (Phenergan) Injection (Currently in Shortage) • Remifentanil (Ultiva) Lyophilized Powder for Solution Injection (Currently in Shortage) Anesthesia • Atropine Sulfate Injection (Currently in Shortage) • Bupivacaine Hydrochloride and Epinephrine Injection, USP (Currently in Shortage) • Bupivacaine Hydrochloride Injection, USP (Currently in Shortage) • Ketamine Injection (Currently in Shortage) • Lidocaine Hydrochloride (Xylocaine) Injection (Currently in Shortage) • Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine (Currently in Shortage) • Methadone Hydrochloride Injection (Currently in Shortage) • Ropivacaine Hydrochloride Injection (Currently in Shortage) Anti-Infective • Cefazolin Injection (Currently in Shortage) • Cefepime Injection (Currently in Shortage) • Cefotaxime Sodium (Claforan) Injection (Currently in Shortage) • Cefotetan Disodium Injection (Currently in Shortage) • Cycloserine Capsules, USP (Currently in Shortage) • Erythromycin Lactobionate for Injection, USP (Currently in Shortage) • Gemifloxacin Mesylate (Factive) Tablets (Currently in Shortage)
    [Show full text]
  • Surgical Antibiotic Prophylaxis
    Surgical Antibiotic Prophylaxis - Adult Page 1 of 6 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. Local microbiology and susceptibility/resistance patterns should be taken into consideration when selecting antibiotics. Patients scheduled for surgery should have the following antibiotics administered prior to their procedure: ● Vancomycin, ciprofloxacin/levofloxacin, and gentamicin are to be initiated 60 to 120 minutes prior to incision, and all other antibiotics are to be initiated within 60 minutes of incision ● Carefully evaluate allergy histories before using alternative agents - the majority of patients with listed penicillin allergies can safely be given cephalosporins or carbapenems ● If the patient has multiple known antibiotic drug allergies, is colonized with or has a history of a recent multi-drug infection, administer antibiotics as indicated or consider an outpatient Infectious Diseases consultation ● Discontinue all antibiotics within 24 hours of first dose except for: 1) Treatment of established infection, 2) Prophylaxis of prosthesis in the setting of postoperative co-located
    [Show full text]
  • The New Fifth-Generation Cephalosporins – a Balance Between Safety and Efficacy
    REVIEWS Ref: Ro J Pharm Pract. 2020;13(3) DOI: 10.37897/RJPhP.2020.3.2 The new fifth-generation cephalosporins – a balance between safety and efficacy Aura Rusu1, Ioana-Andreea Lungu2 1 Pharmaceutical and Therapeutical Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania 2 Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania Abstract Cephalosporins are beta-lactam antibiotics classified into five generations. The newest generation has three representa- tives: ceftaroline fosamile, the combination ceftolozane/tazobactam (cephalosporin/beta-lactamase inhibitor), and ceftobi- prole medocaril. These new cephalosporins are valuable anti-infective agents, with potent activity against multidrug-re- sistant bacteria, and with a positive balance between benefits and side effects. However, the fifth-generation cephalosporins should be judiciously used to prevent the occurrence of bacterial resistance phenomenon. Keywords: cephalosporins, ceftaroline, ceftolozane, ceftobiprole, MRSA, community-acquired pneumonia, complicated skin and soft tissue infections INTRODUCTION emerged as a result of increased only, in the situation where other Cephalosporins (CFs) are beta- bacterial resistance to classical antibacterial drugs were not lactam antibiotics with numerous antibiotics. Based on the efficient. representatives widely used in the antimicrobial activity, the CFs are therapy
    [Show full text]